# ADRD Treatment and Care Management Guidelines

This document provides evidence-based guidelines for pharmacological treatment, non-pharmacological interventions, care planning, caregiver support, and safety management in dementia.

## ðŸ’Š PHARMACOLOGICAL TREATMENT GUIDELINES

### Cholinesterase Inhibitors

**Korean Dementia Association Clinical Practice Guidelines (2025)**
Dement Neurocogn Disord 2025;24(1):1-15

**Strong Recommendations:**
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for Alzheimer's disease to improve cognition and daily function
- Strong recommendation for Lewy body dementia
- Conditional recommendation for vascular dementia and Parkinson's disease dementia

**Approved Medications:**

| Medication | Starting Dose | Target Dose | Administration |
|------------|---------------|-------------|----------------|
| **Donepezil** | 5 mg daily | 10-23 mg daily | Once daily, evening |
| **Rivastigmine** | 1.5 mg BID | 6 mg BID or 9.5-13.3 mg patch daily | With meals; patch is preferred for GI side effects |
| **Galantamine** | 4 mg BID | 12 mg BID or 24 mg ER daily | With meals |

**Efficacy:**
- Pooled trials demonstrate ~1.4 point improvement on 30-point MMSE over 6 months
- Benefits seen in cognition, global function, and activities of daily living
- Symptomatic treatment; does not modify disease course

**Side Effects (up to 30% of patients):**
- Gastrointestinal: nausea, vomiting, diarrhea
- Neurological: headache, dizziness, insomnia
- Cardiovascular: bradycardia, syncope
- Other: muscle cramps, weight loss

**Contraindications/Cautions:**
- Cardiac conduction abnormalities
- Active peptic ulcer disease
- Asthma/COPD (cholinergic effects)
- Urinary obstruction

**Monitoring:**
- ECG at baseline and periodically (especially donepezil)
- Weight monitoring
- GI symptoms
- Cognitive and functional assessments every 6 months

### Memantine

**Indication:** Moderate to severe Alzheimer's disease

| Parameter | Details |
|-----------|---------|
| **Starting Dose** | 5 mg daily |
| **Titration** | Increase by 5 mg weekly |
| **Target Dose** | 10 mg BID or 28 mg ER daily |
| **Renal Adjustment** | Reduce dose if CrCl <30 mL/min |

**Efficacy:**
- Significant improvements in cognition and function in moderate-severe AD
- May be used as monotherapy or added to cholinesterase inhibitor
- Better tolerated than cholinesterase inhibitors

**Side Effects:**
- Dizziness, headache, confusion
- Constipation
- Hypertension (rare)

**Additional Uses:**
- May improve behavioral symptoms
- May help REM sleep behavior disorder in LBD/PDD

### Combination Therapy

- May add memantine to cholinesterase inhibitor for moderate-severe AD
- Fixed-dose combination (donepezil 10 mg + memantine ER 28 mg) available
- No evidence that combination is superior to monotherapy in mild AD

### Behavioral and Psychological Symptom Management

**Korean Dementia Association BPSD Guidelines (2025)**
Dement Neurocogn Disord 2025;24(1):16-29

**First-Line: Non-pharmacological interventions** (see below)

**Pharmacological Options by Symptom:**

**Depression:**
- SSRIs preferred: sertraline 25-100 mg, citalopram 10-20 mg (max 20 mg due to QTc)
- Avoid tricyclics (anticholinergic)
- Mirtazapine for poor appetite/insomnia

**Anxiety:**
- SSRIs first-line
- Buspirone 5-15 mg BID
- Avoid benzodiazepines (falls, paradoxical agitation, cognitive worsening)

**Agitation/Aggression:**
- Trial of cholinesterase inhibitor adjustment first
- Citalopram 10-20 mg (evidence for agitation)
- Trazodone 25-100 mg (especially evening agitation)
- Antipsychotics: ONLY for severe symptoms with danger to self/others

**Antipsychotic Warnings:**
âš ï¸ **FDA Black Box Warning**: Increased mortality in elderly with dementia
- Use lowest effective dose for shortest duration
- Risk of stroke, death, metabolic effects, parkinsonism
- Requires informed consent discussion
- Avoid in DLB (severe sensitivity)

**Preferred antipsychotics (if necessary):**
- Risperidone 0.25-1 mg
- Quetiapine 12.5-100 mg (preferred in DLB/PDD)
- Aripiprazole 2-10 mg

**Sleep Disturbances:**
- Melatonin 3-10 mg (first-line)
- Trazodone 25-50 mg
- Suvorexant 10-20 mg (approved for insomnia in dementia)
- Avoid benzodiazepines and anticholinergics

**Psychosis:**
- Consider triggers (UTI, medication, pain)
- Cholinesterase inhibitors may help in DLB
- Pimavanserin 34 mg (approved for PD psychosis, used off-label)
- Low-dose antipsychotics if severe/dangerous

### Emerging Treatments

**Disease-Modifying Anti-Amyloid Therapies:**

**Lecanemab (Leqembi):**
- FDA approved January 2023
- 10 mg/kg IV every 2 weeks
- 27% slowing of decline on CDR-SB at 18 months
- Eligibility: Early AD (MCI or mild dementia), amyloid-positive
- Risks: ARIA (amyloid-related imaging abnormalities) - edema and microhemorrhages
- Requires MRI monitoring

**Donanemab:**
- FDA approved July 2024
- Monthly IV infusion until amyloid clearance
- 35% slowing of decline in some studies
- Similar eligibility and monitoring to lecanemab

**Contraindications for Anti-Amyloid Therapy:**
- APOE Îµ4 homozygotes (higher ARIA risk)
- Anticoagulation use
- More than 4 microhemorrhages on MRI
- Superficial siderosis

---

## ðŸ¥ NON-PHARMACOLOGICAL INTERVENTIONS

### Cognitive Interventions

**NICE Guideline NG97 Recommendations:**

**Cognitive Stimulation Therapy (CST):**
- Group-based program of themed activities
- 14 sessions over 7 weeks, then maintenance
- Evidence for mild-moderate dementia
- Improves cognition and quality of life

**Cognitive Rehabilitation:**
- Individual goal-focused approach
- Compensatory strategies for specific deficits
- Memory aids (calendars, lists, labels)
- Environmental modifications

**Reality Orientation:**
- Orientation boards with date/time/location
- Consistent daily routines
- Person-centered approach (avoid correction that causes distress)

### Physical Activity

**AAN Practice Guideline (2018):**
- Twice-weekly exercise program improves physical fitness
- May improve function and reduce behavioral symptoms
- No evidence for slowing cognitive decline

**Recommendations:**
- Aerobic exercise 150 min/week (walking, swimming)
- Strength training 2x/week
- Balance exercises for fall prevention
- Supervised if safety concerns

### Behavioral Interventions

**ABC Approach:**
- **A**ntecedents: Identify triggers
- **B**ehavior: Describe the behavior objectively
- **C**onsequences: What happens after

**Environmental Modifications:**
- Reduce noise and stimulation
- Adequate lighting (reduce sundowning)
- Safe wandering paths
- Remove hazards and triggers

**Communication Strategies:**
- Simple, short sentences
- One question/instruction at a time
- Visual cues and gestures
- Allow processing time
- Avoid arguing or correcting

### Music and Art Therapy

- Personalized music reduces agitation
- Improves mood and engagement
- Can be used for procedural tasks (bathing)
- Art therapy improves well-being

---

## ðŸ”’ SAFETY MANAGEMENT GUIDELINES

### Driving Assessment

**AAN Practice Parameter (2010):**

**When to assess:**
- At diagnosis of dementia
- CDR â‰¥1 strongly associated with unsafe driving
- Any crash, traffic violation, or getting lost

**Assessment Tools:**
- On-road evaluation (gold standard)
- Driving simulation
- Neuropsychological testing (visuospatial, attention)

**Recommendations:**
- CDR 0.5: Close monitoring, possible restrictions
- CDR 1.0: Most should not drive; on-road eval if uncertain
- CDR â‰¥2: Should not drive

**Documentation:**
- Document assessment and recommendation
- Know state reporting requirements
- Provide alternative transportation resources

### Home Safety

**American Occupational Therapy Association Guidelines:**

**Kitchen:**
- Remove knobs from stove or install auto-shutoff
- Supervise cooking
- Remove dangerous items (knives, chemicals)

**Bathroom:**
- Grab bars, non-slip mats
- Adjust water heater (<120Â°F)
- Supervise if fall risk

**Throughout Home:**
- Remove throw rugs, clutter
- Adequate lighting (nightlights)
- Secure medications
- Door alarms if wandering risk
- Consider GPS locator

**Fire Safety:**
- Remove matches/lighters
- Install smoke/CO detectors
- Consider supervised smoking or cessation

### Wandering Prevention

**Risk Factors:**
- History of wandering
- Restlessness, pacing
- Sleep disturbances
- Previous elopement

**Interventions:**
- Door alarms, motion sensors
- Safe Return program (Alzheimer's Association)
- GPS tracking device
- Medical ID bracelet
- Satisfy need to walk (safe walking paths)

### Medication Management

**Assessment Questions:**
- Can they describe medications and purposes?
- Can they open containers?
- Do they take medications correctly (pill counts)?

**Interventions by Level:**
- Mild impairment: Pill organizers, reminders
- Moderate: Daily supervision
- Severe: Full administration by caregiver

---

## ðŸ“‹ CARE PLANNING GUIDELINES

### Advance Care Planning

**Timing:** Early in disease while capacity remains

**Components:**
1. **Values Discussion:** What matters most to the person?
2. **Healthcare Proxy/POA:** Who will make decisions?
3. **Living Will:** Preferences for life-sustaining treatment
4. **Dementia-Specific Directive:** Preferences for feeding, hospitalization in advanced dementia

**Resources:**
- dementia-directive.org (free dementia-specific form)
- PREPARE for Your Care (prepareforyourcare.org)
- Five Wishes document

### Capacity Assessment

**When to Assess:**
- Questionable decision-making
- Major financial/medical decisions
- Legal requirements (POA execution)

**Domains:**
- Understand relevant information
- Appreciate situation and consequences
- Reason about options
- Express a choice

**Note:** Capacity is decision-specific (may have capacity for some decisions but not others)

### Palliative Care Integration

**When to Consider:**
- At diagnosis (concurrent with disease management)
- Focus shifts from cure to comfort

**Components:**
- Symptom management
- Psychosocial/spiritual support
- Goals of care discussions
- Support for family

### Hospice Referral Criteria

**General Guidelines for Dementia:**
- FAST Stage 7C or beyond
- Unable to ambulate, dress, bathe independently
- Incontinence
- Limited meaningful speech
- Plus one of: aspiration pneumonia, pyelonephritis, sepsis, weight loss >10% in 6 months, albumin <2.5

**Medicare Hospice Benefit:**
- Prognosis of 6 months or less if disease runs normal course
- Goals of comfort care
- Forgo life-prolonging treatment

---

## ðŸ‘¥ CAREGIVER SUPPORT GUIDELINES

### Caregiver Assessment

**Domains to Assess:**
- Physical health
- Mental health (depression, anxiety)
- Burden level (Zarit Burden Interview)
- Social support
- Financial concerns
- Knowledge and skills

**Warning Signs of Caregiver Burnout:**
- Sleep problems
- Weight changes
- Getting sick more often
- Anger, irritability
- Withdrawal from activities
- Feeling hopeless

### Caregiver Interventions

**REACH II Intervention (Evidence-Based):**
- Information about dementia
- Safety assessment
- Self-care and healthy behaviors
- Social support enhancement
- Problem-solving skills

**Skills Training:**
- Managing behavioral symptoms
- Communication techniques
- Activities of daily living assistance
- Stress management

**Respite Care:**
- In-home respite
- Adult day programs
- Residential respite

### Caregiver Resources

**National Resources:**
- Alzheimer's Association 24/7 Helpline: 1-800-272-3900
- Family Caregiver Alliance: caregiver.org
- ARCH National Respite Network: archrespite.org
- Eldercare Locator: 1-800-677-1116

**Support Groups:**
- In-person and virtual options
- Disease-specific (e.g., FTD caregiver groups)
- Early-stage for persons with dementia and partners

### Financial Assistance

**Potential Resources:**
- Medicaid waiver programs
- Veterans Administration benefits
- Area Agency on Aging programs
- National Family Caregiver Support Program
- Private long-term care insurance

---

## ðŸ“Š MONITORING AND FOLLOW-UP

### Recommended Schedule

**Every 3-6 months:**
- Cognitive assessment (MMSE/MoCA)
- Functional status review
- Behavioral symptom review
- Medication review and tolerability
- Caregiver status check

**Annually:**
- Comprehensive reassessment
- Update care plan
- Review advance directives
- Safety assessment update

### Parameters to Monitor

**Cognition:** Change from baseline, rate of decline
**Function:** ADL/IADL status
**Behavior:** New or worsening BPSD
**Medical:** Weight, falls, infections
**Medications:** Efficacy, side effects, adherence
**Caregiver:** Burden, health, support needs

---

## ðŸ“š KEY REFERENCES

### Treatment Guidelines
1. Korean Dementia Association. Clinical Practice Guidelines for Dementia. *Dement Neurocogn Disord* 2025;24(1):1-29
2. NICE Guideline NG97. Dementia: assessment, management and support for people living with dementia and their carers. 2018
3. APA Clinical Practice Guideline for Treatment of Patients with Dementia. 2022

### Care Management
4. Alzheimer's Association. Dementia Care Practice Recommendations. 2018
5. Livingston G, et al. Dementia prevention, intervention, and care. *Lancet* 2020;396:413-446
6. van der Steen JT, et al. White paper defining optimal palliative care in older people with dementia. *Palliat Med* 2014;28:197-209

### Caregiver Support
7. Brodaty H, Donkin M. Family caregivers of people with dementia. *Dialogues Clin Neurosci* 2009;11:217-228
8. Belle SH, et al. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups (REACH II). *Ann Intern Med* 2006;145:727-738

---

*This resource should be used in conjunction with clinical judgment and individualized patient assessment. Guidelines are updated regularly; verify current recommendations.*
